Direct Healthcare Professional Communication (DHPC) on glatiramer acetate: anaphylactic reactions may occur months up to years after treatment initiation
2024.08.19
Active substance: glatiramer acetate
The marketing authorisation holders of glatiramer acetate-containing medicinal products, in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM), inform that anaphylactic reactions may occur shortly after the administration of glatiramer acetate, even months to years after the start of treatment. Cases with a fatal outcome have been reported.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN